BDgene

Study Report

Basic Info
Reference
Citation Jackson, K. J., et al. (2013). "Variants in the 15q25 gene cluster are associated with risk for schizophrenia and bipolar disorder." Psychiatr Genet 23(1): 20-28.
Disease Type Bipolar Disorder & Schizophrenia
Study Design case-control
Study Type Candidate-gene association study, Meta-analysis
Sample Size Molecular Genetics of Schizophrenia (GAIN) EA:1151 cases and 723 controls; Molecular Genetics of Schizophrenia (GAIN) AA: 915 cases and 657 controls; Molecular Genetics of Schizophrenia non-GAIN: 1066 cases and 1049 controls; Clinical Antipsychotic Trials of Intervention Effectiveness-White: 351 cases and 381 controls; Clinical Antipsychotic Trials of Intervention Effectiveness-Black: 88 cases and 89 controls; Irish Case-Control Study of Schizophrenia: 988 cases and 587 controls; Irish Study of High Density Schizophrenia Families: 1337 (267 families), 496 cases and 841 controls; Whole Genome Wide Association Study of Bipolar Disorder (GAIN-BD) EA: 641 cases and 410 controls; Whole Genome Association Study of Bipolar Disorder (GAIN-BD) AA: 139 cases and 100 controls; Wellcome Trust Case Control Consortium: 1998 cases and 3004 controls
SNP/Region/Marker Size 5 SNPs
Predominant Ethnicity
Gender Molecular Genetics of Schizophrenia (GAIN) EA: 1105 males/769 females; Molecular Genetics of Schizophrenia (GAIN) AA: 802 males /770 females; Molecular Genetics of Schizophrenia non-GAIN: 1216 males /899 females; Clinical Antipsychotic Trials of Intervention Effectiveness-White: 630 males/102 females; Clinical Antipsychotic Trials of Intervention Effectiveness-Black: 128 males/49 females; Irish Case-Control Study of Schizophrenia: 1018 males/587 females; Irish Study of High Density Schizophrenia Families: 769 males/568 females; Whole Genome Wide Association Study of Bipolar Disorder (GAIN-BD) EA: 474 males/577 females; Whole Genome Association Study of Bipolar Disorder (GAIN-BD) AA: 84 males/155 females; Wellcome Trust Case Control Consortium: 2223 males/2779 females
Age Group adults : Molecular Genetics of Schizophrenia (GAIN) EA: mean age=47.6 (s.d. 15.1); Molecular Genetics of Schizophrenia (GAIN) AA: mean age=44.4 (s.d. 11.9); Molecular Genetics of Schizophrenia non-GAIN: mean age=46.1 (s.d. 15.7); Clinical Antipsychotic Trials of Intervention Effectiveness-White: mean age=41 (s.d. 11.4); Clinical Antipsychotic Trials of Intervention Effectiveness-Black: mean age=40.9 (s.d. 10.1); Irish Case-Control Study of Schizophrenia: mean age=42.3 (s.d. 13.6); Irish Study of High Density Schizophrenia Families: mean age=49.5 (s.d. 14.9); Whole Genome Wide Association Study of Bipolar Disorder (GAIN-BD) EA: mean age=47.6 (s.d. 15.7); Whole Genome Association Study of Bipolar Disorder (GAIN-BD) AA: mean age=44.3 (s.d. 11.5)

Detail Info

Genetic factors reported by this study for BD
SNPs reported by this study for BD (count: 5)

Genes reported by this study for BD (count: 3)

Genetic factors reported by this study for SZ and/or MDD
SNPs reported by this study for SZ/MDD
Disease SNP Related Gene(s) Statistical Values Description Result Category
SZ rs17487223 CHRNB4 P-value=0.03, OR=1.08, 95% CI=(0.98-1.14) in SZD; P-value=0.009, OR=1.07, 95% CI=(1.02-1.13) in SZD + BD; P-value=0.018, OR=1.21, 95% CI=(1.06-1.43) in SZD with the presence of negative symptoms of schizophrenia Two variants, rs8040868 and rs17487223, were significantly associated with risk for schizophrenia. When the schizophrenia and bipolar disorder results were combined, four markers, rs951266, rs16969968, rs8040868, and rs17487223, were significantly associated with risk for schizophrenia and bipolar disorder. A meta-analysis of the results revealed a significant association with the variants rs951266, rs1051730, rs8040868, and rs1748722, and the presence of negative symptoms. Positive
SZ rs8040868 CHRNA3 P-value=0.004, OR=1.09, 95% CI=(1.03-1.16) in SZD; P-value=0.007, OR=1.07, 95% CI=(1.02-1.12) in SZD + BD; P-value=0.02, OR=1.16, 95% CI=(1.02-1.31) in SZD with the presence of negative symptoms of schizophrenia Two variants, rs8040868 and rs17487223, were significantly associated with risk for schizophrenia. When the schizophrenia and bipolar disorder results were combined, four markers, rs951266, rs16969968, rs8040868, and rs17487223, were significantly associated with risk for schizophrenia and bipolar disorder. A meta-analysis of the results revealed a significant association with the variants rs951266, rs1051730, rs8040868, and rs1748722, and the presence of negative symptoms. Positive
SZ rs951266 CHRNA5 P-value=0.15, OR=1.05, 95% CI=(1.02-1.18) in SZD; P-value=0.009, OR=1.07, 95% CI=(1.02-1.13) in SZD + BD; P-value=0.017, OR=1.19, 95% CI=(1.03-1.37) in SZD with the presence of negative symptoms of schizophrenia When the schizophrenia and bipolar disorder results were combined, four markers, rs951266, rs16969968, rs8040868, and rs17487223, were significantly associated with risk for schizophrenia and bipolar disorder. A meta-analysis of the results revealed a significant association with the variants rs951266, rs1051730, rs8040868, and rs1748722, and the presence of negative symptoms. Positive
SZ rs1051730 CHRNA3 P-value=0.19, OR=1.05, 95% CI=(0.97-1.13) in SZD; P-value=0.08, OR=1.05, 95% CI=(0.99-1.1) in SZD + BD; P-value=0.019, OR=1.19, 95% CI=(1.03-1.37) in SZD with the presence of negative symptoms of schizophrenia A meta-analysis of the results revealed a significant association with the variants rs951266, rs1051730, rs8040868, and rs1748722, and the presence of negative symptoms. Positive
SZ rs16969968 CHRNA3 CHRNA5 P-value=0.09, OR=1.06, 95% CI=(0.97-1.13) in SZD; P-value=0.04, OR=1.06, 95% CI=(1-1.11) in SZD + BD; P-value=0.07, OR=1.15, 95% CI=(0.99-1.34) in SZD with the presence of negative symptoms of schizophrenia When the schizophrenia and bipolar disorder results were combined, four markers, rs951266, rs16969968, rs8040868, and rs17487223, were significantly associated with risk for schizophrenia and bipolar disorder. Positive

Genes reported by this study for SZ/MDD
Disease Gene Description Result Category
SZ CHRNA5 Variants in the 15q25 gene cluster are associated with risk for schizophrenia/bipolar illness, negative symptoms of schizophrenia, and influence CHRNA5 expression in the brain and peripheral blood mononuclear cells. Positive
SZ CHRNB4 Variants in the 15q25 gene cluster are associated with risk for schizophrenia/bipolar illness, negative symptoms of schizophrenia, and influence CHRNA5 expression in the brain and peripheral blood mononuclear cells. Positive
SZ CHRNA3 Variants in the 15q25 gene cluster are associated with risk for schizophrenia/bipolar illness, negative symptoms of schizophrenia, and influence CHRNA5 expression in the brain and peripheral blood mononuclear cells. Positive